The role of GLP-1 receptor agonists in CVD prevention
10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Leicester, UK - Online CMEVideo navigation menu
Cardiometabolic multimorbidity 00:27
Key challenges in managing T2DM patients 04:06
Therapies to reduce diabetes-related complications 05:26
GLP-1RAs: multifactorial effects beyond glycemic control 07:29
CV outcome trials with GLP-1RAs 08:26
Recommendations by end/diabetology & cardiology societies 09:57
Educational information
This lecture by prof. Kamlesh Khunti was part of a CME accredited symposium "Reducing CV risk in diabetes: the next preventive challenge".
Faculty
Prof. Kamlesh Khunti is professor of primary care diabetes and vascular medicine at the University of Leicester, UK.
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.
Online-CME
This is available as accredited online CME on coursepath for members. Click the button below to enroll:
EnrollThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: